Hypothalamic loss of Snord116 and Prader-Willi syndrome hyperphagia: The buck stops here?

Juan A. Rodriguez, Jeffrey M. Zigman

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Hyperphagia and obesity are the best-known manifestations of Prader-Willi syndrome (PWS) and are responsible for most of the overall morbidity and mortality associated with the disease. Yet these PWS symptoms remain poorly understood and without effective pharmacologic therapies. Mouse models attempting to recapitulate both the genetic alterations and marked hyperphagia plus obesity of PWS have been enigmatic, leading to skepticism about the use of mouse models to investigate PWS. In this issue of the JCI, Polex-Wolf and colleagues challenge the skeptics by successfully inducing hyperphagia following bilateral mediobasal hypothalamic deletion of the Snord116 gene from adult mice. Obesity also resulted, although only in a subset of mice. While this approach represents an exciting advance, highlighting a pathologic effect of loss of mediobasal hypothalamic Snord116 expression on the development of PWS's hallmark symptoms, the variability in the body-weight and body composition responses to this siteselective gene deletion raises several questions.

Original languageEnglish (US)
Pages (from-to)900-902
Number of pages3
JournalJournal of Clinical Investigation
Volume128
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Prader-Willi Syndrome
Hyperphagia
Obesity
Gene Deletion
Body Composition
Body Weight
Morbidity
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hypothalamic loss of Snord116 and Prader-Willi syndrome hyperphagia : The buck stops here? / Rodriguez, Juan A.; Zigman, Jeffrey M.

In: Journal of Clinical Investigation, Vol. 128, No. 3, 01.03.2018, p. 900-902.

Research output: Contribution to journalReview article

@article{e09efb548b214306a3bfcddb39e8a08c,
title = "Hypothalamic loss of Snord116 and Prader-Willi syndrome hyperphagia: The buck stops here?",
abstract = "Hyperphagia and obesity are the best-known manifestations of Prader-Willi syndrome (PWS) and are responsible for most of the overall morbidity and mortality associated with the disease. Yet these PWS symptoms remain poorly understood and without effective pharmacologic therapies. Mouse models attempting to recapitulate both the genetic alterations and marked hyperphagia plus obesity of PWS have been enigmatic, leading to skepticism about the use of mouse models to investigate PWS. In this issue of the JCI, Polex-Wolf and colleagues challenge the skeptics by successfully inducing hyperphagia following bilateral mediobasal hypothalamic deletion of the Snord116 gene from adult mice. Obesity also resulted, although only in a subset of mice. While this approach represents an exciting advance, highlighting a pathologic effect of loss of mediobasal hypothalamic Snord116 expression on the development of PWS's hallmark symptoms, the variability in the body-weight and body composition responses to this siteselective gene deletion raises several questions.",
author = "Rodriguez, {Juan A.} and Zigman, {Jeffrey M.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1172/JCI99725",
language = "English (US)",
volume = "128",
pages = "900--902",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

TY - JOUR

T1 - Hypothalamic loss of Snord116 and Prader-Willi syndrome hyperphagia

T2 - The buck stops here?

AU - Rodriguez, Juan A.

AU - Zigman, Jeffrey M.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Hyperphagia and obesity are the best-known manifestations of Prader-Willi syndrome (PWS) and are responsible for most of the overall morbidity and mortality associated with the disease. Yet these PWS symptoms remain poorly understood and without effective pharmacologic therapies. Mouse models attempting to recapitulate both the genetic alterations and marked hyperphagia plus obesity of PWS have been enigmatic, leading to skepticism about the use of mouse models to investigate PWS. In this issue of the JCI, Polex-Wolf and colleagues challenge the skeptics by successfully inducing hyperphagia following bilateral mediobasal hypothalamic deletion of the Snord116 gene from adult mice. Obesity also resulted, although only in a subset of mice. While this approach represents an exciting advance, highlighting a pathologic effect of loss of mediobasal hypothalamic Snord116 expression on the development of PWS's hallmark symptoms, the variability in the body-weight and body composition responses to this siteselective gene deletion raises several questions.

AB - Hyperphagia and obesity are the best-known manifestations of Prader-Willi syndrome (PWS) and are responsible for most of the overall morbidity and mortality associated with the disease. Yet these PWS symptoms remain poorly understood and without effective pharmacologic therapies. Mouse models attempting to recapitulate both the genetic alterations and marked hyperphagia plus obesity of PWS have been enigmatic, leading to skepticism about the use of mouse models to investigate PWS. In this issue of the JCI, Polex-Wolf and colleagues challenge the skeptics by successfully inducing hyperphagia following bilateral mediobasal hypothalamic deletion of the Snord116 gene from adult mice. Obesity also resulted, although only in a subset of mice. While this approach represents an exciting advance, highlighting a pathologic effect of loss of mediobasal hypothalamic Snord116 expression on the development of PWS's hallmark symptoms, the variability in the body-weight and body composition responses to this siteselective gene deletion raises several questions.

UR - http://www.scopus.com/inward/record.url?scp=85053248933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053248933&partnerID=8YFLogxK

U2 - 10.1172/JCI99725

DO - 10.1172/JCI99725

M3 - Review article

C2 - 29376891

AN - SCOPUS:85053248933

VL - 128

SP - 900

EP - 902

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -